Prosecution Insights
Last updated: July 17, 2026
Application No. 18/807,978

PREPARATION OF INDOLONE-3YL-HYDRAZONO-SUBSTITUTED 1,3-THIAZOLIDINONE DERIVATIVES AND APPLICATION THEREOF

Non-Final OA §112
Filed
Aug 18, 2024
Priority
Feb 27, 2022 — CN 202210181997.X +1 more
Examiner
SEAMAN, D MARGARET M
Art Unit
Tech Center
Assignee
Fudan University
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
3m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
1068 granted / 1394 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
39 currently pending
Career history
1418
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
20.2%
-19.8% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1394 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 08/18/2024 which is a CON of PCT/CN2023/078485 (02/27/2023) which claims foreign priority to CN 202210181997.X (02/57/2022). Claims 1-7 are before the Examiner. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-5 and 7 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for compounds where R1 is alkyl and halogen and R2 is CF3, halogen and alkyl, does not reasonably provide enablement for compounds where either of R1 or R2 is CN NO2, COOH or SO2H or any other electron withdrawing group or phenyl, SH, or NH2 or any other alkyl electron donating group. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. The examples of compounds made have R1 and R2 being CF3, halogen, C(CH3)3 and methyl. The specification does not define what is a member of an electron-withdrawing group or electron-donating group. The only definition comes from the six examples of compounds that have been made. The specification does not teach towards any member of an electron withdrawing or electron donating group other than the ones specifically made in the six examples. Due to this, the specification does not enable the R1 or R2 groups other than CF3, halogen or alkyl. It is suggested that the claims be amended such that R1 and R2 are limited to being alkyl, halogen and CF3. Claim Objections Claims 2 and 6 are objected to because of the following informalities: These claims depend from a rejected base claim but would be allowable if rewritten in independent form with all of the intervening limitations. Appropriate correction is required. Allowable Subject Matter The closest art is CN 114634506, CN114634501 and CN 114634500 which all teach similar compounds. However, none of these publications are prior art to the instant application. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Aug 18, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679828
METHOD FOR PREPARING LIFITEGRAST
4y 1m to grant Granted Jul 14, 2026
Patent 12679814
SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS
3y 1m to grant Granted Jul 14, 2026
Patent 12673919
PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES
4y 5m to grant Granted Jul 07, 2026
Patent 12668575
N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
2y 11m to grant Granted Jun 30, 2026
Patent 12662497
BENZAZEPINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
2y 10m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
85%
With Interview (+8.0%)
2y 2m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1394 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month